Tower Research Capital (TRC)’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-620	Closed	–	–	6910
2022 Q2	$0	Sell	620 -3,316	-84%	-$2.32K	﹤0.01%	6983
2022 Q1	$6K	Sell	3,936 -8,987	-70%	-$11.4K	﹤0.01%	4998
2021 Q4	$31K	Sell	12,923 -30,422	-70%	-$132K	﹤0.01%	3206
2021 Q3	$231K	Buy	+43,345	New	+$390K	0.01%	1683

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Tower Research Capital (TRC)'s CRXT Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 620 shares.

Tower Research Capital (TRC) first reported a position in CRXT in Q3 2021 and held it in 4 quarters. The position peaked at $231K in Q3 2021. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Tower Research Capital (TRC) reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 620 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022.
Tower Research Capital (TRC) first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
Tower Research Capital (TRC)'s Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $231K in Q3 2021.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.